264 completed. 264 Phase 1, 58 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 264 | Completed 264 |
| Phase 2 | 58 | Completed 58 |
Follow Malaria: new trials by email Literature Review of Malaria trials Research Report on Malaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Drug-Interaction Assessment of GSK3772701 in Healthy Male and Female Participants Aged 18 to 55 Years Midazolam (MDZ), GSK3772701 - Malaria, Falciparum | Phase 1 | Completed | GlaxoSmithKline | 20 | 2026-06-26 | 2026-09-30 |
| Safety and Immunogenicity of SUM-101 Malaria Vaccine in Children and Infants Living in Burkina Faso SUM-101 - Malaria,Falciparum | Phase 1 | Completed | European Vaccine Initiative | 39 | 2025-08-01 | 2026-09-11 |
| First-in-Human PfSPZ-LARC2 Vaccination/CHMI PfSPZ Vaccine, PfSPZ (7G8) Challenge, Sodium Chloride, 0.9% - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 22 | 2025-07-23 | 2026-08-17 |
| Controlled Human Malaria Infection by Mosquito Bites Using a Local Strain of Plasmodium Falciparum Controlled Human Malaria Infection - Malaria (Plasmodium Falciparum) | Phase 1 | Completed | Centre de Recherche Médicale de Lambaréné | 20 | 2025-07-18 | 2026-09-11 |
| Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population MAM01 300 mg SC, MAM01 300 mg IM, MAM01 2000 mg IV - Healthy Volunteers | Phase 1 | Completed | Gates Medical Research Institute | 125 | 2025-03-28 | 2026-06-03 |
| Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso PfSPZ-LARC2 Vaccine, Normal Saline (Placebo) - Malaria Falciparum, Malaria Infection | Phase 1 | Completed | Sanaria Inc. | 75 | 2025-03-04 | 2026-04-16 |
| Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants MMV371 LAI, Placebo for MMV371 - Malaria,Falciparum | Phase 1 | Completed | Medicines for Malaria Venture | 32 | 2024-08-27 | 2026-05-05 |
| L9LS MAb in Malian Infants L9LS, Placebo, R21/Matrix-MTM - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 327 | 2024-08-19 | 2026-10-01 |
| Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali TB31F, Normal saline - Malaria,Falciparum | Phase 1 / Phase 2 | Completed | Radboud University Medical Center | 167 | 2024-07-12 | 2026-01-22 |
| A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003) Plasmodium falciparum, MK-7602, Artemether/lumefantrine - Malaria | Phase 1 | Completed | Merck Sharp & Dohme LLC | 16 | 2024-04-18 | 2025-01-13 |
| A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™ R21/Matrix M™ (Group 1), R21/Matrix M™ (Group 2), R21/Matrix M™ (Group 3) - Malaria,Falciparum | Phase 1 | Completed | University of Oxford | 36 | 2024-03-25 | 2026-10-21 |
| A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants GSK4024484C, Placebo - Malaria, Falciparum | Phase 1 | Completed | GlaxoSmithKline | 123 | 2023-12-11 | 2026-07-08 |
| A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria BNT165c, BNT165d, Placebo - Malaria | Phase 1 / Phase 2 | Completed | BioNTech SE | 163 | 2023-11-13 | 2026-08-28 |
| Pan-Malaria Transmission-Blocking Vaccine AnAPN1 Vaccine AnAPN1 - Malaria | Phase 1 | Completed | Centre de Recherche Médicale de Lambaréné | 33 | 2023-09-11 | 2025-05-02 |
| Assessment of the Malaria Vaccine Candidate SumayaVac-1 in Healthy Adults Aged 18-45 Years Living in a Malaria Endemic Country SumayaVac-1(SUM-101), Verorab - Malaria | Phase 1 | Completed | Swiss Tropical & Public Health Institute | 40 | 2023-08-25 | 2024-04-15 |
| A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines RH5.1 and/or RH5.2-VLP with Matrix-M - Malaria, Malaria,Falciparum | Phase 1 / Phase 2 | Completed | University of Oxford | 41 | 2023-08-18 | 2026-07-20 |
| Piperaquine Granule Formulation Relative Bioavailability and Food Effect Study in Healthy Volunteers. Piperaquine Tetraphosphate uncoated tablets, Piperaquine Tetraphosphate dispersible granules - Malaria | Phase 1 | Completed | Medicines for Malaria Venture | 60 | 2023-08-14 | 2025-03-18 |
| Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults MAM01 1.5 mg/kg, Placebo, MAM01 5 mg/kg - Malaria | Phase 1 | Completed | Gates Medical Research Institute | 63 | 2023-08-14 | 2026-06-12 |
| Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults Pvs230D1-EPA/Matrix-M - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 105 | 2023-08-04 | 2025-12-01 |
| Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum MMV367 3mg, P. falciparum IBSM infection, MMV367 5mg - Infections, Vector Borne Diseases | Phase 1 | Completed | Medicines for Malaria Venture | 12 | 2023-08-01 | 2025-12-10 |
Showing 20 of 264. Sign in to see all of them.
Malaria, Falciparum (103) · Malaria, Vivax (15) · Parasitemia (8) · Infections (6) · Parasitic Diseases (4) · Burkitt Lymphoma (3) · Malaria, Cerebral (3) · Protozoan Infections (3) · Adenoviridae Infections (2) · Glucosephosphate Dehydrogenase Deficiency (2) · HIV Infections (2) · HIV Seropositivity (2) · Hemolysis (2) · Vector Borne Diseases (2)
Mosquito-Borne Diseases (264) · Vector Borne Diseases (262) · Protozoan Infections (261) · Parasitic Diseases (260) · Infections (258) · Pathological Conditions, Signs and Symptoms (11) · Pathologic Processes (9) · Virus Diseases (9) · Sepsis (8) · Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Inflammation (7) · Systemic Inflammatory Response Syndrome (7) · DNA Virus Infections (5)
Saline Solution (15) · Artemether, Lumefantrine Drug Combination (12) · Primaquine (11) · Chloroquine (9) · Matrix-M (7) · Artesunate (6) · Rabies Vaccines (6) · Aluminum Hydroxide (5) · Lumefantrine (5) · ProMune (5) · Sodium Chloride (5) · artefenomel (5) · atovaquone, proguanil drug combination (5) · fanasil, pyrimethamine drug combination (5) · tafenoquine (5)
National Institute of Allergy and Infectious Diseases (NIAID) (47) · University of Oxford (47) · Medicines for Malaria Venture (37) · U.S. Army Medical Research and Development Command (22) · Sanaria Inc. (20) · GlaxoSmithKline (12) · London School of Hygiene and Tropical Medicine (5) · Novartis Pharmaceuticals (5) · Radboud University Medical Center (5) · European Vaccine Initiative (4) · Pfizer (3) · Swiss Tropical & Public Health Institute (3) · University of Mississippi, Oxford (3) · sigma-tau i.f.r. S.p.A. (3) · BioNTech SE (2)
United States (77) · United Kingdom (50) · Mali (21) · Australia (19) · Burkina Faso (11) · Netherlands (11) · Tanzania (10) · Kenya (7) · Switzerland (7) · The Gambia (6) · France (4) · Gabon (4) · Germany (4) · Thailand (4) · Uganda (4)
Patrick E Duffy, M.D. (7) · Adrian VS Hill, D.Phil, FRCP (5) · James McCarthy, Prof (5) · Adrian V S Hill, MD (4) · Ulrike Lorch, MD FRCA FFPM (4) · Adrian V Hill, DPhill FRCP (3) · Adrian VS Hill (3) · Adrian VS Hill, MA, BM BCh, DPhil, DM (3) · Isabelle Borghini Fuhrer, PhD (3) · Salim Abdulla, MD, PhD (3) · Sara A Healy, M.D. (3)
PMID 39787798, PMID 40245769, PMID 41014333, PMID 23526949, PMID 23899517, PMID 25211344, PMID 26292027, PMID 26292257, PMID 27695088, PMID 29389671, PMID 31932368, PMID 32239164, PMID 32275867, PMID 33717176, PMID 34194041, PMID 39324693, PMID 39708824, PMID 39805302, PMID 41176969, PMID 10190913, PMID 10501745, PMID 12663340, PMID 12742586, PMID 1313024, PMID 15069048, PMID 16904798, PMID 17075340, PMID 17428147, PMID 17940609, PMID 18213374, PMID 18231580, PMID 18253503, PMID 18270560, PMID 18378716, PMID 18545693, PMID 18612426, PMID 18698359, PMID 18930565, PMID 19093004, PMID 19390585, PMID 19569965, PMID 19673614, PMID 20107498, PMID 20140214, PMID 21058417, PMID 21352601, PMID 21410944, PMID 21745716, PMID 21752262, PMID 21799809
2019 (3), 2015 (2), 2016 (2), U01CI000211 (2), 2014 (1), 2018 (1), 5UM1AI148684-04 (1), N01AI085346 (1), R01AI025136 (1), R01HL086488 (1), R01NS074409 (1), U01AI065683 (1), U19AI065683 (1)